Michael A. Gorin, MD, a urologist with Urology Associates in Cumberland, Maryland, discusses biomarkers for diagnosing prostate cancer, including PSA, mpMRI, and serum and urine tests. He offers an overview of the history of prostate specific antigen (PSA), emphasizing that PSA screening is advantageous even as he acknowledges that PSA’s high level of sensitivity and low specificity lead to lots of unneeded biopsies. There are now many serum and urine biomarker tests that can assist provide more uniqueness, including 4KScore, Prostate Health Index, SelectMDx, and ExoDx Prostate IntelliScore (EPI), all of which are endorsed by the NCCN Standards. Dr. Gorin keeps in mind that, when price is considered, SelectMDx and EPI outperform the other tests. Dr. Gorin concludes the presentation by going over how multiparametric MRI must be used in prostate cancer medical diagnosis, keeping in mind that while there is little official assistance on this yet, he utilizes it in his own practice if a patient has a PSA ≥ 3 and gets an irregular outcome from a serum or urine biomarker test.